Janux Therapeutics, Inc. (NASDAQ:JANX) Holdings Raised by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ boosted its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 492.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 205,167 shares of the company’s stock after buying an additional 170,520 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned approximately 0.39% of Janux Therapeutics worth $10,771,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its stake in shares of Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after purchasing an additional 156,675 shares during the last quarter. Lester Murray Antman dba SimplyRich increased its stake in shares of Janux Therapeutics by 205.3% during the 4th quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company’s stock worth $1,301,000 after purchasing an additional 16,351 shares during the last quarter. Algert Global LLC acquired a new position in shares of Janux Therapeutics during the 3rd quarter worth $1,112,000. Ally Bridge Group NY LLC acquired a new position in shares of Janux Therapeutics during the 3rd quarter worth $4,943,000. Finally, FMR LLC increased its stake in shares of Janux Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after purchasing an additional 47,075 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $30.68 on Friday. The company has a 50-day moving average of $39.00 and a 200-day moving average of $46.96. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -26.22 and a beta of 3.23. Janux Therapeutics, Inc. has a 52 week low of $28.92 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Leerink Partners increased their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Scotiabank lowered their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 28th. Finally, BTIG Research raised their target price on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $92.44.

Insider Transactions at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at $4,507,788.32. This trade represents a 13.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the acquisition, the director now directly owns 10,141,287 shares in the company, valued at $314,582,722.74. The trade was a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 50,002 shares of company stock valued at $2,684,703. Company insiders own 29.40% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.